These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25518397)

  • 1. [Present situation and new challenges for medical treatment of Kawasaki disease].
    Ikeda K; Hamaoka K
    Nihon Rinsho; 2014 Sep; 72(9):1523-9. PubMed ID: 25518397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Methylprednisolone pulse therapy in Kawasaki disease].
    Miura M; Matsuoka M; Kohno K; Ohki H; Yoshiba S
    Nihon Rinsho; 2008 Feb; 66(2):338-42. PubMed ID: 18265457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunoglobulin therapy].
    Ogata S; Ishii M
    Nihon Rinsho; 2014 Sep; 72(9):1617-22. PubMed ID: 25518412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti TNF-α (infliximab) treatment for intravenous immunoglobulin (IVIG) resistance patients with acute Kawasaki disease the effects of anticytokine therapy].
    Saji T; Takatsuki S; Kobayashi T
    Nihon Rinsho; 2014 Sep; 72(9):1641-9. PubMed ID: 25518416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Plasma exchange therapy for Kawasaki disease refractory to intravenous immunoglobulin].
    Mori M
    Nihon Rinsho; 2008 Feb; 66(2):349-54. PubMed ID: 18260334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Kawasaki disease: what you need to know].
    Bajolle F; Laux D
    Arch Pediatr; 2012 Nov; 19(11):1264-8. PubMed ID: 22921712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
    Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease.
    Ichiyama T; Ueno Y; Hasegawa M; Ishikawa Y; Matsubara T; Furukawa S
    Rheumatology (Oxford); 2005 Mar; 44(3):314-7. PubMed ID: 15572393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
    Kuo HC; Wang CL; Liang CD; Yu HR; Chen HH; Wang L; Yang KD
    J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
    J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The B cell superantigen-like interaction of intravenous immunoglobin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy.
    Leucht S; Uttenreuther-Fischer MM; Gaedicke G; Fischer P
    Clin Immunol; 2001 Apr; 99(1):18-29. PubMed ID: 11286538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An elevated value on drug-induced lymphocyte stimulation test for immunoglobulin is an immunological abnormality of Kawasaki disease.
    Nomura Y; Masuda K; Eguchi T; Morita Y; Ueno K; Kawano Y
    Int Arch Allergy Immunol; 2010; 153(1):102-6. PubMed ID: 20357491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kawasaki disease with severe cardiac sequelae: lessons from recent New Zealand experience.
    Wilson N; Heaton P; Calder L; Nicholson R; Stables S; Gavin R
    J Paediatr Child Health; 2004; 40(9-10):524-9. PubMed ID: 15367145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of Guidelines for the Medical Treatment of Acute Kawasaki Disease in Japan (2020 Revised Version) and Positioning of Plasma Exchange Therapy in the Acute Phase.
    Mori M; Matsubara T
    Pediatr Infect Dis J; 2023 Sep; 42(9):e328-e332. PubMed ID: 37200509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
    Kobayashi T; Kobayashi T; Morikawa A; Ikeda K; Seki M; Shimoyama S; Ishii Y; Suzuki T; Nakajima K; Sakamoto N; Arakawa H
    J Pediatr; 2013 Aug; 163(2):521-6. PubMed ID: 23485027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease.
    Tsujimoto H; Takeshita S; Nakatani K; Kawamura Y; Tokutomi T; Sekine I
    Clin Immunol; 2002 May; 103(2):161-8. PubMed ID: 12027421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
    Chen S; Dong Y; Yin Y; Krucoff MW
    Heart; 2013 Jan; 99(2):76-82. PubMed ID: 22869678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease.
    Yoshimura K; Kimata T; Mine K; Uchiyama T; Tsuji S; Kaneko K
    J Pediatr; 2013 Jun; 162(6):1205-9. PubMed ID: 23290510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive therapies for Kawasaki disease.
    Campbell AJ; Burns JC
    J Infect; 2016 Jul; 72 Suppl():S1-5. PubMed ID: 27241708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.
    Hwang JY; Lee KY; Rhim JW; Youn YS; Oh JH; Han JW; Lee JS; Burgner D
    Arch Dis Child; 2011 Nov; 96(11):1088-90. PubMed ID: 20551193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.